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Bispecific antibodies (bsAbs) combine the functionality of two antibodies in one molecule.
Two bsAb-drugs are currently on the market (one recently approved) and more are in
clinical development. Driven by large pharma, bsAbs are emerging as
next-generation biologics.
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Bispecific antibodies (bsAbs) combine specificities of two antibodies and
simultaneously address different antigens or epitopes. BsAbs with ‘two-
target’ functionality can interfere with multiple surface receptors or ligands
associated, for example with cancer, proliferation or inflammatory
processes. BsAbs can also place targets into close proximity, either to support
protein complex formation on one cell, or to trigger contacts between cells.
Examples of ‘forced-connection’ functionalities are bsAbs that support
protein complexation in the clotting cascade, or tumor-targeted immune
cell recruiters and/or activators. Following years of research and
development (R&D), the first bsAb was approved in 2009. Another
bsAb entered the market in December 2014 and several more are in clinical
trials. Here, we describe the potentials of bsAbs to become the next wave of
antibody-based therapies, focusing on molecules in clinical development.
Recombinant bispecific antibodies
The concept of recombinant bispecific prototype immunoglobulin (Ig)-G-like antibodies was
devised more than two decades ago. Morrison and colleagues fused flexible linker peptides to the
C termini of the heavy chains of IgG followed by single-chain variable domains with different
binding specificities [1]. The molecules could be differentiated from ‘normal’ antibodies because
they had dual functionalities. Technical hurdles initially hampered further development, causing
bsAbs to remain a topic of R&D primarily in the academic and biotech environment. However,
rapidly evolving technologies that enabled the engineering, production, and development of
recombinant protein derivatives, combined with renewed interest from the pharmaceutical
industry, then jump-started the bsAb research field. Today, many different bsAb formats suitable
for the development of therapeutic proteins are available [2–17]. Originating frequently in
academic environments, several protein formats have proven to be robust enough to support
their clinical application. This has subsequently triggered significant interest and ‘buy-in’ from
pharmaceutical companies (including Roche, Pfizer, Genentech, Sanofi, Abbvie, Chugai, Amgen,
and others), which are now developing bsAb therapeutics.
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different, purified monoclonal antibodies (mAbs) or by fusing two
hybridomas resulting in a quadroma cell line producing, among
others, bispecific IgG molecules [18]. Over the past two decades,
genetic engineering has resulted in a range of recombinant bispe-
cific antibody formats, with over 50 different formats now avail-
able [2]. This has revolutionized the development of bsAb for
therapeutic and diagnostic applications, enabling researchers to
adjust the size, valency, flexibility, half-life, and biodistribution of
bsAb to fit the desired target–product profile.
Generally, bsAb can be divided into two major classes, those
bearing an Fc region and those lacking an Fc region, the latter
normally being smaller than the IgG and IgG-like bispecific mole-
cules comprising an Fc (Fig. 1). The Fc region facilitates purifica-
tion of the bsAb, using protocols established for IgG molecules,
and can contribute to improved solubility and stability. Further-
more, the presence of an Fc region also has consequences for Fc-
mediated effector functions, which might be desirable add-ons for
therapeutic applications, such as antibody-dependent cellular
cytotoxicity (ADCC), complement fixation (CDC), and the long
half-life resulting from their larger size and FcRn-mediated recy-
cling processes [19]. These functions can further be adopted by
genetic engineering, for example, by eliminating ADCC and/orBivalent
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FIG. 1
Schematic overview of the different strategies used to generate bispecific
antibodies (bsAbs) derived from the antigen-binding sites of two different
antibodies. Symmetric bsAb are generated by the assembly of antibodies
with unmodified heavy chain constant regions, such as by the
heterodimerization of heavy chains from two different antibodies or
homodimerization of heavy chains extended by an additional binding site
resulting in bivalent or tetravalent molecules. Using heavy chains modified to
force heterodimerization (e.g., using a knobs-into-holes strategy) results in
asymmetric bsAb. Alternatively, two different antibody fragments, such as
scFv, can be fused to a non-immunoglobulin protein, such as albumin.
Furthermore, two antigen-binding fragments can be directly fused, resulting
in small bsAb molecules. Finally, bsAb can also be generated by chemical
conjugation of two different antibodies.CDC while maintaining the long half-life. By contrast, bsAb lack-
ing an Fc region rely entirely on their antigen-binding capacity to
exert their therapeutic activities.
Bispecific IgG molecules can be assembled from two different
heavy and light chains expressed in the same producer cell.
However, because of random assembly of the different chains,
this results in a substantial number of nonfunctional molecules in
respect to bispecificity. A simple solution to this problem is the
fusion of a second binding moiety, for example a single-chain Fv
fragment or a domain antibody to the N or C terminus of the heavy
or light chain, respectively, of an antibody, resulting in tetravalent
molecules with two binding sites for each antigen (Fig. 1). Double-
variable domain (DVD)-Igs also belong to this class of symmetric
bispecific IgG and IgG-like molecules. Here, a second variable
heavy chain domain (VH) is fused to the VH of a heavy chain
and a second variable light chain domain (VL) is fused to the light
chain (Fig. 2) [20]. Alternatively, dual recognition can be achieved
by selecting VH and VL domains capable of binding to two
different antigens (Fig. 2). These two-in-one antibodies are biva-
lent and indistinguishable from normal IgG molecules.
A breakthrough in the generation of bivalent, bispecific IgG
molecules was the development of the knobs-into-holes technol-
ogy [12]. Here, heavy-chain heterodimerization was forced by
introducing different mutations into the two CH3 domains, result-
ing in asymmetric antibodies. Variations of this general approach
have been established over recent years, for example using alter-
native mutations [21], electrostatic steering effects [22], or hybrid
CH3 domains derived from IgG and IgA [13]. However, all these
approaches suffer from the so-called ‘light-chain problem’, that is,
random pairing of the two different light chains with the two
chains of the heavy chain heterodimer. This can be circumvented
by the use of a common light chain, which enables binding to both
antigens. However, this might not be possible for all antibodies. In
such cases, bacterial expression and assembly of knob- or hole-
containing half-antibodies, each containing the matching light-
heavy chain combination, can be applied [15]. An elegant solution
was provided by CrossMab technology [16]. Here, correct pairing
of the light chains is achieved by exchanging the CH1 domain of
one heavy chain with the constant (CL) domain of the correspond-
ing light chain (Fig. 2). More recently, mutations were also intro-
duced into the CH1–CL as well as the VH–VL interface of the Fab
fragments, thus enforcing correct pairing of the light chains with
the corresponding heavy chains [23]. Of note, asymmetric heavy
chains can also serve as building blocks to generate trivalent,
bispecific, or even trispecific antibodies by fusing a further anti-
gen-binding moiety to one of the heavy chains [6].
Small bsAb lacking an Fc region either comprise the variable VH
and VL domains of two antibodies, or are based on Fab fragments.
A simple format, which is utilized for example in the Bispecific T
cell Engager (BiTE1) technology, is the genetic fusion of two scFv
fragments resulting in tandem scFv molecules. Here, the two scFv
moieties form independent folding units connected in a flexible
manner through a peptide linker [24]. An alternative approach is
based on the diabody format. Here, the variable domains from two
antibodies, A and B, are expressed as two polypeptide chains,
VHA–VLB and VHB–VLA, with the domains connected by a short
peptide linker, forcing heterodimerization of the two chains [25].
The bivalent diabody format was further improved by thewww.drugdiscoverytoday.com 839
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FIG. 2
Various bispecific antibodies (bsAbs) are currently in clinical development or are already approved for cancer therapy. The upper two lines depict immunoglobulin
(Ig)-like bsAbs comprising an IgG Fc region, either as bivalent or tetravalent molecules. Furthermore, several small bsAb and bsAb fusion proteins have entered
clinical trials. Abbreviations: BiTE, bispecific T cell engager; DART, Dual affinity retargeting; DNL, dock-and-lock; DVD-Ig, dual variable domain immunoglobulins;
HSA, human serum albumin; kih, knobs into holes.
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tetravalent derivatives thereof, so-called ‘tandAb’ molecules with
two binding sites for each antigen [27], as well as disulfide-stabi-
lized variants, such as the dual-affinity retargeting molecules
(DART) [28]. The small size of these molecules, as well as the lack
of the Fc region, leads to rather rapid renal elimination in vivo.
Although the small size might be advantageous regarding tissue
penetration (e.g., in tumor therapy), the short plasma half-lives
affects dosing (i.e., frequent injections or infusions are required).
The implementation of half-life extension moieties, including
conjugation of polyethylene glycol (PEG), fusion of PEG-mimetic
polypeptides, or albumin-binding moieties, might be useful [29].
BsAbs can also be generated by fusing different antigen-binding
moieties (e.g., scFv or Fab) to other protein domains, which
enables further functionalities to be included. For example, two
scFv fragments have been fused to albumin, which endows the
antibody fragments with the long circulation time of serum albu-
min [30,31]. Another example is the ‘dock-and-lock’ approach840 www.drugdiscoverytoday.combased on heterodimerization of cAMP-dependent protein kinase
A and A kinase-anchoring protein [32]. These domains can be
linked to Fab fragments and entire antibodies to form multivalent
bsAb [33].
Figure 1 shows schematically an overview of the different
strategies used to obtain bsAb formats by different groups in
academia, and the biotech and pharma industries. Most of these
formats are still in preclinical evaluation and many might remain
at this stage. However, some formats have made it already into
clinical development and are detailed in Table 1 and discussed
below. The composition and features of bsAb formats that are in
clinical development are depicted in Fig. 2.
Recruitment and activation of immune cells
Quadroma bsAbs for T cell recruitment: Trion Pharma
The anti-epithelial cell adhesion molecule (EpCAM)/anti-CD3
bsAb catumaxomab (Removab1) was the first bsAb to receive
market approval [34]. Trion Pharma developed catumaxomab as
Drug Discovery Today  Volume 20, Number 7  July 2015 REVIEWS
TABLE 1
bsAbs in clinical development
Molecule Targets Format MOA Indication Statusa Developed by
Catumaxomab EPCAM + CD3 TrioMab T cell recruitment Malignant ascites Market Fresenius Biotech (Trion)
Ovary cancer 2
Gastric cancer 2
Epithelial cancer 1–2
Lymphomun FBTA05 CD20 + CD3 TrioMab T cell recruitment BCL 1–2 Fresenius Biotech (Trion)
Ertumaxomab Her2-CD3 TrioMab T cell recruitment Metastatic breast cancer 1 Fresenius Biotech (Trion)
Blinatumomab
AMG103 MT103
CD19 + CD3 BiTE T cell recruitment B cell ALL Market Amgen (Micromet)
ALL relapsed refractory 2
ALL pediatric 1–2
MT111 CEA + CD3 BiTE T cell recruitment Gastric cancer advanced
adenocarcinoma
1b Amgen (Micromet)
MT112 BAY2010112 PSMA + CD3 BiTE T cell recruitment Prostate cancer 1 Bayer (Micromet)
MT110 AMG 110 EPCAM + CD3 BiTE T cell recruitment Colorectal cancer 1 Amgen (Micromet)
Lung and gastrointestinal
cancer
1
RG7221 Angiopoietin
2 + VEGF
CrossMab Two-ligand inactivation Colorectal cancer 2 Roche
RG6013 FXI + FX CLC-IgG Two-factor dimerization Hemophilia A 2 Chugai (Roche group)
RG7597 Her1 + Her3 DAF-IgG Two-RTK inactivation Head and neck cancer,
colorectal cancer
2 Genentech (Roche group)
RG7716 Angiopoietin
2 + VEGF
CrossMab Two-ligand inactivation Wet AMD 1 Roche
MM111 Her2 + Her3 scFv2-HSA Two-RTK inactivation Advanced gastric and
esophageal cancer
2 Merrimack
MM141 IGF1R + Her3 IgG-scFv Two-RTK inactivation Advanced solid tumors 1 Merrimack
ABT122 TNFalpha + IL17 DVD-IgG Two-ligand inactivation RA and inflammation 1–2 Abbvie
ABT981 IL1a + IL1b DVD-IgG Two-ligand inactivation Osteoarthritis 1–2 Abbott
MGD006 CD123 + CD3 DART T cell recruitment AML 1 Macrogenics and Servier
MGD007 GPA33 + CD3 DART-Fc T cell recruitment Colorectal cancer 1 MacroGenics and Servier
BI1034020 beta amyloid
two epitopes
Bi-nanobody Double epitope binding Alzheimer’s disease 1 Ablynx
(Boehringer Ingelheim)
ALX0761 IL17A + IL17F Bi-nanobody Two-ligand inactivation Inflammatory disease 1 Ablynx (Merck Serono)
SAR156597 IL4 + IL13 TBTI (DVD)-IgG Two-ligand inactivation IPF 1 Serono
TF2 CEA + hapten D&L Fab3 Payload delivery Colorectal cancer 1 Immunomedics
IL-17/IL-34 biAb IL23 + IL17 scFv-Fc Two-ligand inactivation Inflammatory and
autoimmune disease
1 BMS (Zymogenetics)
AFM13 CD30 + CD16 TandAb NK cell recruitment Hodgkin’s disease 1 Affimed
AFM11 CD19 + CD3 TandAb T cell recruitment NonHodgkin’s lymphoma 1 Affimed
LY3164530 Her1 + cMET orthoFab-IgG Two-RTK inactivation Solid tumors 1 Eli Lilly
a 1, phase I clinical trials; 2, phase 2 clinical trials.
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murine IgG2a and rat IgG2b. It targets the tumor, recruits T
effector cells via binding to the CD3e
´
subunit of the T cell receptor
complex, and also activates monocytes, macrophages, dendritic
cells, and NK cells by Fcg-receptor binding [35]. This induces the
killing of, and thus reduction in, tumor cells in patients with
ovarian carcinoma (Fig. 3A), preventing or reducing the accumu-
lation of ascites. As a ‘first-generation’ bsAb, catumaxomab is a
nonhuman IgG-like rat–mouse hybrid antibody and binds a dif-
ferent antigen with each arm. It is produced by mouse–rat quad-
romas. Preparations of correct heterodimeric antibodies areobtained by differentiating the desired molecule from undesired
monospecific rat- or mouse-only antibodies, and from contami-
nants with wrongly associated L-chains. L-chain mispairing can
also be reduced given that rat L-chains favor association with the
rat H-chain and vice versa; mouse H-and L-chains also associate
preferentially [36].
Catumaxomab is potent with acceptable safety. It requires
administration of only small doses (10–150 mg) four to five times
by intraperitoneal infusions over 9–13 days. In addition to being
approved for the treatment of malignant ascites, catumaxomab is
currently also in clinical trials for application in ovarian cancerwww.drugdiscoverytoday.com 841
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FIG. 3
Mode of action of therapeutic bispecific antibodies (bsAbs). (a) Recruiting of T cells or natural killer (NK) cells to tumors is achieved by entities that bind to tumor
cell surface antigens as well as to immune cells. Examples are TrioMabs (catumaxomab), BiTEs (blinatumomab), DARTs, and TandAbs. (b) Interference with
receptor signaling is achieved by binding cell surface receptors or to their cognate ligands. BsAbs in various formats have been developed for this mode of action,
such as DVD-Igs, DAFs, 2-in1-IgG, Tv-IgGs, and CrossMabs. (c) One exciting ‘unusual’ application of bsAbs is antibody-mediated forced assembly of the coagulation
Xase complex. A heterodimeric common light chain IgG connects FXIa and FX and thereby overcomes FVIII deficiency. Abbreviations: BiTE, bispecific T cell
engager; DAF, dual-action Fab; DART, Dual affinity retargeting; DNL, dock-and-lock; DVD-Ig, dual variable domain immunoglobulins; FX, Factor X; HSA, human
serum albumin; Ig, immunoglobulin; kih, knobs into holes; Tv, tetravalent.
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Table 1). Given that catumaxomab is a rat–mouse hybrid, some
anti-rat IgG or anti-mouse IgG responses are observed in most
patients; however, efficacy of the treatment appears not to be
significantly affected.
A series of additional bsAbs have been generated using the
quadroma technology, including bsAbs that target CD3 as well
as CD20 or human epidermal growth factor receptor 2 (HER2), and
other cancer antigens, such as the gangliosides GD2 and GD3 [34–
42]. All bsAbs were active in preclinical evaluations and two are
currently in clinical trials: ertumaxomab (Rexomun1) targets
tumor cells by binding to HER2, recruits T cells via its anti-CD3
arm and is currently in a phase 1 trial in patients with metastatic
breast cancer [42]. Lymphomun targets the CD20 antigen on B
cells and recruits T cells to those cells via its anti-CD3 arm. It is
currently in a phase 1–2 trial in patients with B cell lymphoma.
BiTEs for T cell recruitment: Amgen (Micromet)
Whereas Trion Pharma approached immune cell recruitment with
large IgG-like bsAbs that contain Fc regions and, hence, have a
rather long serum half-life, Micromet (now Amgen) applied a
conceptually different format to achieve effector cell recruitment
using BiTEs [43,44]. These are small entities comprising only the
variable regions of antibodies in the form of scFvs that are con-
nected by flexible linker peptides [44–46]. They are produced as
recombinant proteins in CHO cells and contain only two antigen-
binding sites. One is directed at a tumor-associated cell surface
antigen (with higher affinity than to CD3) and the other binds
CD3 with lower affinity [44]. Given their small size and lack of Fc
region, BiTEs have a short serum half-life. However, they are
potent and can induce specific antitumoral cytotoxicity (target
lysis of cultured cells) at concentrations as low as 10 pg/ml [47,48]
in cell culture. Thereby, BiTEs are not ‘consumed’ but, as recruiter
molecules, enable repeated rounds of target cell lysis by T cells at
low effector:target cell ratios [49,50].842 www.drugdiscoverytoday.comThe BiTE that is most advanced in clinical development is blina-
tumomab (AMG103, MT103) [45], which binds the CD19 antigen
on acute lymphoblastic leukemia (ALL) cells and demonstrated high
potency (tumor eradication) in many preclinical models [51,52].
Given its potency and to ameliorate risks, blinatumomab is applied
to patients at a very low dose (as low as 0.005–0.06 mg/m2). The
pharmacokinetics (PK; short half-life) also mandates an appropriate
dosing schedule of continuous infusion over several weeks to ensure
continuous activation of T cells against target cells. Blinatumomab
is currently in phase 3 trials (NCT02013167) for minimal residual
disease ALL, and additionally in phase 2 for ALL, in phase 1–2 in
relapsed ALL, and in phase 1 for pediatric ALL [53]. Recently
(December 2014), blinatumomab (BlincytoTM) was approved by
the US Food and Drug Administration (FDA) for the treatment of
patients with Philadelphia chromosome-negative precursor B cell
ALL (B cell ALL). Chronic lymphocytic leukemia (CLL) B cells can be
depleted by blinatumomab in the presence of autologous T cells,
and also in patients pretreated with different chemotherapies [54].
Patients with non-Hodgkin’s lymphoma also showed tumor regres-
sion with blinatumomab [55].
Other BiTEs that have been developed by Micromet bind tumor-
associated antigens EpCAM, HER2, carcinoembryonic antigen
(CEA), ephrin A2 (EphA2), melanoma-associated chondroitin
sulfate proteoglycan (MCSP), or CD33. Clinical studies are ongo-
ing for EpCAM-CD3 binders (MT110, AMG110) in colorectal
cancer, lung cancer and gastrointestinal cancer (all phase 1 trials).
CEA-CD3 binders (MT111) are in phase 1b trials in advanced
gastric adenocarcinoma, and another phase 1 trial is investigating
a prostate-specific membrane antigen (PSMA)-CD3 binder in pros-
tate cancer (MT112, Bay2010112, Bayer).
DARTs for T cell recruitment: Servier and Macrogenics
Macrogenics and its partner Servier develop T cell recruiting
bispecific molecules based on the dual affinity re-targeting (DART)
format. DARTs are diabody-like entities that have the VH of the
Drug Discovery Today  Volume 20, Number 7  July 2015 REVIEWS
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VH of the second variable region linked to the VL of the first
(Fig. 2). Additional disulfide stabilization generates DARTs [56].
MGD006 is a DART that binds the cell surface protein CD123 as
well as CD3. It does not contain an Fc region and, therefore, has a
rather short serum half-life. It recruits T cells to hematological
cancers, has shown promising activity in preclinical evaluation,
and is currently in phase 1 trials in patients with hematological
cancer. Another CD3-binding DART (MGD007) binds to the
GPA33 protein, which is present in gastrointestinal cancers. In
contrast to MGD006, this DART is fused to an Fc region (Fig. 2)
and, therefore, has a prolonged serum half-life. Having completed
preclinical development, investigational new drug (IND) for
MGD007 was filed late 2014 and recruiting for a phase 1 trial
in gastrointestinal cancer is ongoing (ClinicalTrials.gov
NCT02248805)
TandAbs for NK and T cell recruitment: Affimed
AFM13 is a TandAb developed by Affimed to recruit immune cells
to tumors [57]. In contrast to the above-described BiTEs (Micro-
met–Amgen), DARTs (Macrogenics–Servier) and bsAbs (Trion),
immune cell recruiting by AFM13 is not aimed at T cell binding
but instead at NK cells. To achieve this, the first binding entity of
AFM13 binds CD30 and the second binding specificity is directed
at CD16A on NK cells and macrophages. TandAbs are bispecific
fusion proteins with four binding sites, two of which bind to tumor
cell surface antigens and the other two to the immune cells.
TandAbs do not carry Fc domains, are smaller than whole IgGs
or IgG-derived bsAbs, but larger than BiTEs. Therefore, they have a
shorter serum half-life than IgGs but remain longer in the circula-
tion compared with BiTEs (because they exceed the glomerular
filtration cut-off size). AFM13 is currently in clinical phase 1 in
patients with Hodgkin’s disease.
Another TandAb molecule is AFM11, which also recruits im-
mune cells to tumors. In contrast to AFM13, it binds to CD3 on T
cells and mediates simultaneous binding to CD19 on lymphomas
[58]. Thus, its mode of action is similar to the BiTE blinatumomab.
AFM11 is currently in a phase 1 trial in patients with nonHodgkin’s
lymphoma.
Interference with receptor signaling and inactivation of
signaling ligands
Receptor tyrosine kinase (RTKs), such as members of the Her
family or insulin-like growth factor (IGF) receptors, stimulate or
modulate the growth of tumor cells. Thus, they are preferred targets
in cancer therapy; monospecific RTK-targeting IgGs, such as cetux-
imab (ErbituxTM) and panitumumab (VectibixTM), which are
directed against HER1, or trastuzumab (HerceptinTM) and pertuzu-
mab (PerjetaTM) directed against HER2, are already established in
cancer therapy. However, cancer cells can escape growth inhibition
caused by the blockage of one signaling pathway by switching to
another. Therefore, bsAb-mediated simultaneous interference with
two (or more) RTK signaling pathways, by inactivating either the
RTKs or their ligand, should reduce the possibility of such escape
mechanisms and, hence, improve therapeutic efficacy [59,60]. In
a similar manner, receptors that are involved in inflammatory
pathways or their ligands can be used to interrupt pro-inflammatory
signals and treat inflammatory or autoimmune diseases.(scFv)2-HSA and Tetravalent-IgG derivatives (Tv-IgGs) against
Her2 + Her3 or IGF1R+ Her3: Merrimack
MM111 (Merrimack) is a bsAb that targets two HER family members.
Given the four members of this family (HER1/EGFR, HER2, HER3
and HER4), different RTK heterodimers containing HER1, 2, or 3
bind epidermal growth factor (EGF)-related growth factors and
trigger intracellular signaling cascades to promote tumor growth
[59]. One example is HER2, the elevated expression of which in up to
30% of breast carcinomas correlates with shorter overall survival
and reduced time to relapse [60]. Phosphorylation of HER3 was also
observed in HER2-amplified breast cancer [61], and HER2–HER3
heterodimerization contributes to breast cancer development. An
improved growth inhibitory effect of blocking two HER family
members has been demonstrated by simultaneously blocking
HER2 as well as HER3. This can interfere with the growth of cancer
cell lines with HER2 gene amplifications [62], even where HER2
binders by themselves (e.g., trastuzumab and pertuzumab) inhibit
ligand-induced HER3 activation rather weakly [31]. The bsAb
MM111 (Merrimack) binds HER2 as well as HER3 and comprises
two antagonistic scFv fragments, each with one specificity but
linked to each other (Fig. 2). MM111 does not contain a Fc region
but instead has the two scFvs additionally fused to modified human
serum albumin to extend the PK [31]. By binding to HER2 and HER3,
MM111 is a potent inhibitor of the proliferation of HER2-expressing
tumor cells in vitro and in vivo. MM111 is currently in a phase 2 trial
in patients with advanced gastric and/or esophageal cancer.
Another bsAb that has been generated by Merrimack is MM141
[63]. It binds HER3 as well as the non-HER RTK IGF-1R. The
rationale for combining HER3 and IGF1 inhibitors is that IGF1R
signaling is increased in many cancers [63–66] and could provide a
way for tumor cells to escape from other signaling blockades.
Therefore, bsAbs that inhibit HER3- and IGF1R signaling could
overcome or reduce therapy escape of tumor cells. The format of
MM141 is based upon an improved ‘Morrison-Prototype’ format
(Fig. 2). It has stable scFvs added to the constant region of an IgG so
that the bsAb contains four binding regions, two for each specific-
ity. MM141 is a potent inhibitor of the proliferation of IGF1R and
HER3-expressing tumor cells in vitro and in vivo and is currently
undergoing a phase 1 trial in patients with advanced solid tumors.
Dual-action Fab (DAF)-IgG directed at HER1 + HER3: Genentech
RG7597 (Genentech) is a bsAb that binds to HER1 and HER3. The
combination of HER1 and HER3 binding specificities into one
bsAb could improve cancer therapy because complete inhibition
of mitogen-activated protein kinase (MAPK) and AKT signaling
(and subsequent growth arrest of pathway addicted cells) can be
achieved upon simultaneous blockade of HER1 and HER3 signal-
ing [10]. In contrast to most other current bsAb formats, this
antibody is not composed of two different variable regions with
different specificities. Instead, it is a human IgG that has dual
specificity built into one ‘special’ variable region. Smart genetic
engineering, display, and selection technologies were combined to
evolve and isolate binding entities that bind HER1 and HER3 with
good affinities (1.9 nM and 0.4 nM, respectively) [10]. The
presence of a functional Fc region enables this bsAb to behave
like a normal human IgG and to also exert immune effector
functions, such as ADCC. RG7597 is currently being evaluated
in a phase 2 trials in patients with head and neck cancer [67].www.drugdiscoverytoday.com 843
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HER1 and c-Met: Eli Lilly
LY3164530 (Lilly) is a bsAb in phase 1 clinical trials that binds and
inhibits the receptors HER1 and c-MET [23]. This bsAb has a
general IgG shape containing H-chain heterodimers (by forced
heterodimerization) and two different Fab versions (mutated in V
and C domains). This generates an ‘orthogonal interface’ that
causes preferential alignment of the different Fab domains in
the correct assembly. HER1 and c-MET have a role in tumor growth
and metastasis, and simultaneous interference with their receptor
signaling could prove beneficial for therapy compared with the
application of monospecific HER1- or c-MET binders. In addition,
binding HER1 and c-MET by normal bivalent IgGs can by itself
induce receptor signaling, which is triggered by IgG-mediated
dimerization. However, this potential issue is not applicable to
the IgG-like format, which contains only one binding arm for each
antigen.
DVD-IgG directed at receptor ligands TNF+IL-17 and
IL1a + IL1b: Abbott and Abbvie
Interference with receptor–ligand systems is not only applied in
cancer therapy, but also serves as a therapeutic principle in inflam-
matory diseases, such as rheumatoid arthritis (RA). Therefore, bsAbs
that interfere with multiple receptors or ligands are applied in
clinical studies for these indications. ABT122 is a bsAb developed
by Abbvie that binds to the receptor ligand tumor necrosis factor
(TNF) and to interleukin 17 (IL-17). Both factors contribute to
inflammatory diseases, such as RA, and monospecific antibodies
that target these ligands are in the clinic and under development
(e.g., the TNF inhibitors infliximab and adalimumab and the IL-17
inhibitor secukinumab). Given that simultaneous inhibition of TNF
and IL-17 was more efficacious in murine arthritis models, Abbvie
(Abbott) generated bsAbs that bind to and, thus, inactivate both
factors. The DVD-Ig format [19] that was used comprised a whole IL-
17-binding ‘IgG’ (with Fc region) to which additional variable
regions that bind TNF were fused ‘on top’ of the existing variable
regions (Fig. 2). Optimized for binding affinities and ligand access
and being able to bind both targets, the DVD molecule also has a
constant region (human IgG1/k) to provide a long serum half-life.
ABT122 is currently in a phase 1 study in patients with RA [68].
Another DVD-Ig that has been constructed following the same
design principles is ABT981 (Abbott). This molecule interferes with
the functionality of the receptor ligands IL-1a as well as IL-1b [69].
Both factors are validated targets in RA and interference with their
functionality can interrupt pro-inflammatory signaling via their
cognate receptor. Thus, bsAb-mediated simultaneous inhibition is
expected to generate enhanced efficacy. ABT981 is currently also
undergoing a phase 1 trial in patients with RA.
Bi-nanobodies directed at receptor ligands IL-17A + IL-17F or at
two Ab epitopes: Ablynx
ALX0761 (Merck Serono–Ablynx) is a bispecific nanobody that binds
the IL-17 members IL-17F and IL-17A, and is currently in phase 1
evaluation in healthy volunteers [70]. IL-17 and Th17 cells are
associated with inflammatory and autoimmune diseases. Given that
IL17A and IL-17F are important ligands for this signaling, bsAbs that
interfere with the activity of both ligands might be more efficacious
blockers of inflammatory responses compared with monospecific844 www.drugdiscoverytoday.comentities alone. Bispecific nanobodies comprise two monomeric VH-
like binding entities of different specificities that are fused to each
other in a bivalent-bispecific manner. Rather than Fc, these entities
contain a half-life-extending addition to overcome potential PK
issues (prevents otherwise extremely short serum half-lives).
The anti-Ab bsAb BI1034020 (Boehringer Ingelheim–Ablynx) is
another bispecific nanobody derivative with a similar format to
ALX0761 and has been evaluated in a phase 1 study. It comprises
two monodomains with different specificities and contains a PK-
modulating moiety. Generated originally also by Ablynx, this
biparatopic half-life-extended nanobody binds two paratopes
and/or epitopes on the amyloid-beta peptide Ab, rather than
binding two ligands.
Crossmabs directed at the receptor ligands VEGFA and
Angiopoetin 2: Roche
RG7221 (Roche) is a bsAb that inhibits the receptor ligands vascu-
lar endothelial growth factor A (VEGFA) and angiopoietin 2
(Ang2), which have a role in angiogenesis. This bsAb has been
generated by applying the Crossmab format to generate an IgG-
shaped entity that binds each ligand with one arm (Fig. 2). As a
IgG-like molecule that contains a functional Fc region, it has the
PK properties of normal IgGs [16,17]. Tumor vascularization is
necessary for tumor growth and is controlled and modulated by
multiple angiogenic factors; therefore, depletion of angiogenesis
factors, such as VEGF (e.g., by the normal IgG Avastin) can be
applied for tumor therapy. However, tumors can escape antian-
giogenic treatment that inactivates just one factor (e.g., VEGF) by
utilizing other pathways [71,72]. Thus, hitting two or more path-
ways simultaneously (by depleting essential ligands) should
improve antiangiogenic therapy and reduce escape mechanisms.
The target of the IgG bevacizumab (Avastin) is VEGF; bevacizumab
binds to VEGF receptor 1 (VEGFR1) and VEGFR2 and thereby
modulates angiogenesis. Ang2 is a ligand for Tie-2 kinase and,
by binding to its receptor, also contributes to tumor angiogenesis.
Preclinical studies provided evidence that hitting both angiogen-
esis pathways with the bsAb generated better activity in compari-
son to the monospecific Ang2- or VEGFA-binding antibodies [73].
The Crossmab RG7221 is currently being evaluated in phase 2
trials in patients with colorectal cancer [74].
A related Crossmab molecule that also contains binding regions
that recognize VEGFA and Ang2 is RG7716. It is similar in size,
composition, and specificity to the above-described RG7221 Cross-
mab, but has different PK properties. Ligand (VEGFA and Ang2)-
driven angiogenesis poses a problem not only in oncology, but
also in wet age-related macula degeneration (AMD). Therefore, the
RG7716 Crossmab was developed for use in ophthalmology [75],
and is currently in a phase 1 trial in patients with wet AMD.
TBTI (DVD)-IgG directed at receptor ligands IL4 and IL13: Serono
SAR156597 (Serono) is a bsAb that simultaneously binds the
signaling ligands IL4 and IL13, thereby inhibiting signaling of
their cognate receptors. This can reduce IL4- and IL13-dependent
fibroblast activation because a combined blockade of IL4 and IL13
has a greater inhibitory efficacy compared with inhibition of either
factor alone [76]. Therefore, bsAbs that simultaneously inhibit IL4
or IL13 might be suitable for treating fibrotic diseases, in particular
idiopathic pulmonary fibrosis (IPF), a severe disease with currently
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bsAb in IgG-like format that contains additional V-regions at-
tached to its H- and L-chain N termini. This N-terminal tandem
configuration of V-regions (termed ‘TBTI’ for tetravalent bispecific
tandem Ig) is similar in composition to DVD-Igs. SAR156597 is
currently being evaluated in a phase 1 clinical study in patients
with IPF.
ScFv-IgGs directed at receptor ligands IL17 and IL23: BMS–
Zymogenics
The IL17/IL23-binding bi-Mab is a bsAb that can bind both signal-
ing ligands simultaneously and, hence, interfere with their signal-
ing toward their receptors [77]. Simultaneous reduction of IL17
and IL23 signaling is expected to reduce inflammatory reactions
and cytokine releases, and, therefore, might be beneficial for the
treatment of inflammatory or autoimmune diseases. The bsAb
format (from Zymogenetics) contains an Fc region (for benign
PK behavior) to which scFvs with two specificities are fused. IL17/
IL23 bi-Mab is currently in a phase 1 trial in patients with inflam-
matory and autoimmune diseases.
BsAbs for targeted or pretargeted payload delivery
DNL(Fab3) for radiotherapy of CEA-expressing cells:
Immunomedics
BsAbs can not only be applied to crosslink proteins, cells, or to
simultaneously interfere with two targets, but can also serve as
vehicles for targeted or pretargeted delivery of payloads to tumor
cells [32,33,78]. TF2 (Immunomedics) is one bsAb that has been
designed for targeted payload delivery, and is currently being
evaluated in phase 1 studies. It binds to CEA, which is present
on the surface of many solid tumors, including colorectal cancer.
The bsAb can simultaneously bind to and thereby capture a
peptide-’hapten’, a small entity that by itself can be labeled with
radioactive substances [78]. The bsAb comprises three Fab modules
that are stably coupled to each other in a triangular fashion by the
‘dock-and-lock’ technology (Fig. 2) [32,33]. Without a Fc region,
these molecules have a rather short serum half-life, which is an
advantage for pretargeting approaches. TF2 is currently being
evaluated in a pretargeting setting (cold bsAb first followed sepa-
rately by a Lutetium-177-labeled or Indium-111 payload for imag-
ing) in phase 1 trials in patients with advanced colorectal cancer.
Forced association of protein complexes
Common LC-IgG for protein–protein (FXIII) complexation:
Chugai
RG6013 (Chugai) is an IgG derivative with H-chain heterodimer-
ization motifs. This was combined with the common light chain
approach to prevent L-chain mispairing issues [79,80]. The thera-
peutic field of application of RG6013 is differs from those of the
molecules described so far. Bivalent in composition with one armeach binding to one protein, RG6013 was designed and selected to
bring together two protein antigens into one complex. The cog-
nate antigens that are bound by RG6013 are Factor IXa and Factor
X in the coagulation cascade. In healthy subjects, these factors are
brought together by coagulation factor VIIIa, which is missing in
the bleeding disorder hemophilia A. Current treatment of this
severe disorder is a supplementation of FVIII, which can effectively
reduce bleeding complications. However, absence of this protein
(because of gene defects) in patients can lead to provided FVIII
being recognized as a foreign protein, resulting in an immune
response against it. This occurs in as many as 30% of such patients,
who cannot continue treatment with FVIII. In addition, FVIII is
rapidly cleared (half-life of less than 15 h) and is poorly bioavail-
able upon subcutaneous application. The humanized bsAb that
links factor IXa and factor X contains an Fc region that provides a
long serum half-life, which could overcome both limitations
(expected lower immunogenicity and long serum half-life). There-
fore, RG6013 could provide a superior treatment for hemophilia A
compared with existing FVIII supplementation [81,82]. RG6013 is
currently being evaluated in phase 2 trials in patients with hemo-
philia A.
Concluding remarks
Clinical development of bsAb is currently focusing on two main
areas, cancer therapy and inflammatory diseases. The major goal is
to address simultaneously different targets involved in pathophys-
iological processes and thereby increase therapeutic efficacy. Pro-
duction processes are available that enable the generation of bsAbs
in prokaryotic and eukaryotic cells, and even via in vitro translation
without involving living organisms [83]. Other important aspects
to be addressed include identifying optimal application modes and
potentially modulating the PK properties, especially of small-sized
bsAb molecules. In the case of BiTEs, the drug is applied via
continuous intravenous infusion (enabling tight control of drug
levels). Alternatives to that include half-life extension strategies
(e.g., through PEGylation or albumin-binding entities [19,29]). In
cancer therapy, bsAb are being developed for either the retargeting
of immune effector cells for tumor cell destruction (cancer immu-
notherapy) or the neutralization of two different signaling
cascades through inactivation either on the level of the receptor
or the ligands. With a growing number of bsAb entering clinical
trials, it is likely that new bsAb will be approved in the near future.
Importantly, novel strategies are also emerging, as shown for the
substitution of coagulation factor VIII activity by a bsAb, further
supporting the immense potentials of these molecules for disease
therapy.
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